Pharma Generics — Handling regulatory milestone slippage in project plans

ANDA timelines live and die by regulatory milestones you don’t fully control — query responses, inspection windows, approval dates that move.

When a milestone slips, do you re-baseline the whole project, or keep the original baseline and track variance against it? And how do you communicate the downstream impact to commercial teams without re-planning from scratch every time?

Interested in how other generics teams keep plans realistic without constant re-baselining.